Design, Analysis and Testing of a Novel Mitral Valve for Transcatheter Implantation
Mitral regurgitation is a common mitral valve dysfunction which may lead to heart failure. Because of the rapid aging of the population, conventional surgical repair and replacement of the pathological valve are often unsuitable for about half of symptomatic patients, who are judged high-risk. Transcatheter valve implantation could represent an effective solution. However, currently available aortic valve devices are inapt for the mitral position. This paper presents the design, development and hydrodynamic assessment of a novel bi-leaflet mitral valve suitable for transcatheter implantation. The device consists of two leaflets and a sealing component made from bovine pericardium, supported by a self-expanding wireframe made from superelastic NiTi alloy. A parametric design procedure based on numerical simulations was implemented to identify design parameters providing acceptable stress levels and maximum coaptation area for the leaflets. The wireframe was designed to host the leaflets and was optimised numerically to minimise the stresses for crimping in an 8 mm sheath for percutaneous delivery. Prototypes were built and their hydrodynamic performances were tested on a cardiac pulse duplicator, in compliance with the ISO5840-3:2013 standard. The numerical results and hydrodynamic tests show the feasibility of the device to be adopted as a transcatheter valve implant for treating mitral regurgitation.
KeywordsTranscatheter mitral valve implantation (TMVI) Heart valve development Heart valve assessment Mitral valve Bioprosthetic bi-leaflet valve
Mitral regurgitation is one of the major mitral valve pathologies leading to heart failure.27 It is a result of primary anatomical changes affecting the mitral valve leaflets, or left ventricular remodelling which may lead to dislocation of papillary muscles.15 Although mild and moderate mitral regurgitation may be tolerated and do not require surgical intervention, patients with severe symptomatic mitral regurgitation have a very low survival rate in absence of interventions40 which restore the coaptation of the mitral valve leaflets,11 or replace the mitral valve with a prosthetic device.30 While non-randomised reports suggest that repairing techniques have significantly lower mortality rates,54 randomised studies indicate no significant difference in the mortality rates3 between replacement and repair20 in ischemic related mitral regurgitation. Whenever practicable, surgical repair remains the best option for the treatment of degenerative mitral regurgitation.19,20 Nevertheless, in elderly patients surgical intervention is often associated with comorbidities such as diabetes, pulmonary disease, perioperative hemodialysis and low ejection fraction, which increase considerably the risk of operative mortality.5,49 As a result, only a small portion of patients suffering from functional mitral regurgitation and approximately half of those suffering from degenerative mitral regurgitation currently undergo surgery.7 Minimally invasive transcatheter implantation can reduce the risks in these patients and offer an alternative to surgical therapies for mitral valve diseases.34
Transcatheter techniques to treat mitral regurgitation can be classified as leaflet and chordae repair; indirect annuloplasty; left ventricular remodelling; and replacement.25 Leaflet and chordae repair techniques can be effective and durable in a wide variety of pathologies, even without annuloplasty in selected patients.21,36 Indirect annuloplasty releases devices which support remodelling of the annulus in the coronary sinus, improving leaflet coaptation. However this procedure is associated with adverse cardiovascular events, such as myocardial infarction and coronary sinus rupture,24,47 and data available on the short- and long-term outcome are still limited.32,37 Left ventricular remodelling is applied to reduce a dilated left ventricle diameter which may tether the mitral valve leaflets.22 Despite the initial attempts demonstrated benefits, this technique is not available commercially at the moment.
Although these transcatheter techniques can successfully reduce mitral regurgitation, a valve replacement would allow to restore the unidirectional blood flow in a wider patients’ anatomical selection. Transcatheter mitral valve (TMV) replacements, which attempt to conjugate the lessons from surgical mitral valve interventions35,42 with the successful transcatheter aortic valve (TAV) experience, are still in developmental stages. A number of TMVs have been proposed, and are at different stages of evaluation.1,23,41 These are typically adapted from TAVs,41 and adopt the same three leaflets circular configuration. Possible issues that may arise with these devices include suboptimal placement in native mitral position, due to the irregular non-circular shape of the mitral annulus, and recurrence of paravalvular leakage.30 This is known to reduce the survival rates after TAV replacement, and is a more critical problem for mitral valve implants, where the implantation sizes and the peak transvalvular pressures are higher.25
In this paper, a novel mitral valve device suitable for transcatheter implantation, based on a bi-leaflet configuration with D-shaped orifice, is presented. In particular, the development of the proposed valve, in terms of design optimisation and in vivo hydrodynamic assessment is described.
Materials and Methods
Leaflet Design Optimisation and Manufacturing
Leaflets were designed to minimise structural and functional failure. Structural failure typically occurs due to excessive stresses, with the locations of structural failure in explanted bioprosthetic heart valves often associated with the peak regions of maximum principal stress.9 Design optimisation was performed using parametrically-varied CAD models by means of finite element analysis for both structural and functional criteria.
The leaflets were designed in their assembled configuration as surfaces using 3D CAD software Rhinoceros 4.0 (Robert McNeel & Associates), using an inter-trigonal dimension equal to 26 mm. Numerical analyses of structural mechanics were performed using an explicit solver in LS-DYNA (Livermore Software Technology Corporation). The analysis of the twenty-five initial designs provided coaptation area and peak maximum principal stress data for hypertensive systolic loading conditions, i.e. when they are fully closed and a peak of transmitral pressure equal to 200 mmHg is applied.
Glutaraldehyde fixed bovine pericardium was selected as material for the leaflets, due to its long clinical use in bioprosthetic heart valves and favorable hemodynamic performance.26 Calf pericardial sacs were obtained from a local abattoir, and fixed in a 0.5% solution of glutaraldehyde for 48 h, after removing the fat and parietal pericardium by hand.26 Three sets of leaflets were obtained from visually homogeneous regions of the pericardial sac of thickness in the range of 400 μm ±10% (measured using a thickness gauge - Mitutoyo Corporation, Tokyo, Japan). One dumbbell-shaped sample of 4 mm width and 16 mm gauge length was extracted from the unused portion of each patch, using a die cutter.
The coaptation of the leaflets was modelled using a frictionless master-slave contact condition.9 The effect of the inertia of blood in reducing system oscillations was reproduced by using a damping coefficient of 0.9965, consistent with what identified in previous works based on similar simulations.9 Each leaflet was discretised with approximately 1820 quadrilateral 2D constant strain Belytschko-Lin-Tsay shell elements with 5 points of integration across the thickness. The leaflet thickness was set to 0.4 mm, approximating the value selected for the patches used for the valve manufacturing. To simulate leaflet closure, a uniformly distributed opening pressure of 4 mmHg was initially applied to the leaflets, starting from their unloaded position, and then reverted and ramped to a closing pressure of 115 mmHg. This corresponds to the typical mean transmitral systolic pressure difference obtained by testing the valve prototypes in the pulse duplicator, for a cardiac output of 5 L/min, a frequency of 70 beats per minute (with 65% of diastolic time) and a normotensive aortic pressure of 100 mmHg. A minimum safety factor of 3, based on the strength reported for glutaraldehyde fixed bovine pericardial tissue,4 was accepted for the predicted peaks of stress.
Frame Design and Optimisation
The TMV frame is designed to match and support the two leaflets along their constrained edge and provide their anchoring. Its structure is obtained from super elastic NiTi wires of 0.6 mm diameter.
The distal margin of the ventricular structures includes distal loops (portions 1 and 2 in Fig. 2) which act as torsion springs, reducing the levels of stress in the crimped frame and dampening the load experienced by the leaflets during the operating cycles. The loops are also used to host control tethers which allow the valve recollapse into a delivery sheath by adopting the same approach described in Rahmani et al. 45
3D solid models of the wireframe (Fig. 2) were developed using NX CAD (Siemens PLM Software) program. Each solid model was discretised with approximately 110,000 tetrahedral elements of maximum edge size equal to 0.2 mm. The wireframe was modeled as NiTi shape memory alloy by using an austenitic Young’s modulus (E A) of 50 GPa, martensitic Young’s modulus (E M) of 25 GPa, and 0.3 for the Poisson’s ratio of both austenitic and martensitic (ν A , ν M) phases.56 The transformation stresses of the NiTi wire for the austenite start (σ as,s), austenite finish (σ as,f), martensite start (σ sa,s) and martensite finish (σ sa,f) were 380, 400, 250 and 220 MPa respectively.56 The sleeves were modeled as stainless steel by using a Young’s modulus of 210 kN/mm2 and a Poisson’s ratio of 0.3, and were connected to the wireframe by applying stress free projected glued contact to their surfaces. The relative motion between the TMV and catheter during crimping was simulated by fixing the displacement of the top of the loops.
The wireframe geometry was optimised to maintain the maximum von Mises stress below the martensitic yield stress, when crimped to 8 mm (24 French) diameter. Simulations were performed using the FEA software MSC.Marc/Mentat and an implicit solver utilizing single-step Houbolt time integration algorithm, by gradually reducing the diameter of a surround cylindrical contact surface. Critical regions subjected to the highest levels of stress during crimping were identified in the initial geometry and optimised iteratively, using the approach described in Burriesci et al. 10 For each portion indicated in Fig. 2, the length, curvature and angle values were updated in each simulation in order to obtain a parameter set minimising the crimping stress on the wireframe.
Prototypes of the wireframe structure were manufactured by thermomechanical processing of nitinol wires, mechanically joined at specific locations by means of stainless steel crimping sleeves. The leaflets and the sealing cuff made from bovine pericardium were sutured to the inner portions of the frame extensions (portions 5 and 6 in Fig. 2) using polypropylene surgical sutures. The skirt, made from a polyester mesh (Surgical Mesh PETKM2004, Textile Development Associates, USA), was included to gently distribute the anchoring force over the annulus (between portions 5, 6 and 7 in Fig. 2). The nominal valve size of the prototypes, defined based on the inter-trigonal dimension of the designed leaflets, was equal to 26 mm. This is suitable for preclinical in vivo evaluation in large animal models.
Elastic deformation of the wireframe in an 8 mm diameter tube shows that the portions functioning as springs (Fig. 2a: portions 3 and 4) and the portions holding the mitral valve leaflets (Fig. 2a: portions 5 and 6) do not intersect with each other, this leaves sufficient space for the leaflets and sealing cuff when crimped. Additionally, the geometry of the crimped wireframe was in good agreement with the numerical prediction.
Regurgitant fractions did not show a clear pattern with the implantation size, and ranged from 8.2 to 17.8%. However, all prototypes met the minimum performance requirements in the ISO5840-3:2013 standard (regurgitant flow fraction ≤20% for both 23 and 25 mm annuli—no specifications for smaller sizes). The mean diastolic transmitral pressure difference decreased in the larger annuluses and reached a maximum value of about 9 mmHg in the 21 mm annulus, reducing to 5 mmHg in the 25 mm annulus.
The peak (systolic) transmitral pressure difference was 125 mmHg, while the maximum diastolic opening pressure was about 45 mmHg. Regurgitant flow was observed over the ventricular systole, primarily due to paravalvular leakage between the mitral annulus and the device. The closing regurgitation (due to closure of the mitral valve leaflets) was higher in the larger annuluses. Anchoring was adequate for all tests, and no valve migration was observed for any of the test conditions. Typical pressure and flow rate diagrams through the valve, obtained for one of the three prototypes in an annulus of 23 mm over a cardiac cycle, are provided in Fig. 8.
Currently, no device specifically designed for TMV implantation has been approved for the European or American market. However, a number of solutions have been proposed, with many already at the stage of clinical trial (these include the CardiAQ 51,52 and Fortis,2,8 Edwards Lifescience; the Tendyne,39 Tendyne Holdings Inc., Roseville MN, USA; the Tiara,14 Neovasc, Richmond, Canada; the NaviGate, NaviGate Cardiac Structures Inc., Lake Forest, CA, USA; and the Intrepid, Medtronic, Dublin, Ireland).31 Despite the reduced number of patients involved in the trials and the large 30 days mortality rate, justified by the compassionate ground of the implants, this early experience has confirmed the potential benefit of the treatment and the ability of transcatheter solutions to successfully replace the mitral valve function.31 All devices under investigation are based on three occluding leaflet, replicating the configuration and function of semilunar valves. These are supported by self-expanding stents, obtained from laser-cut nitinol tubes, mechanically deformed and thermoset.41 The stents bulge or expand in a flange covered with a fabric material, designed to apply pressure on the atrial inflow portion, and used to minimise paravalvular leakage while counteracting the ventricular anchoring force providing the valve securing. From a technical point of view, a major distinction between the devices currently under investigation is represented by the method they use to generate the ventricular anchoring force, which can be based on ventricular tethers (e.g. Tendyne), native valve anchors (e.g. CardiAQ, Fortis, Tiara and NaviGate) or dual stent structures with barbs.38
The device presented in this paper introduces a number novel concepts, providing new and alternative features. Contrary to competing TMVs, the proposed solution is based on two asymmetric flexible leaflets, describing a D-shape cross section designed to better conform to the irregular anatomy of the valve annulus and minimise the disturbance to the sub-valvular apparati. This allows to maximise the geometrical orifice area of the prosthesis without interfering with the aortic valve anatomy and function. The leaflets are sutured onto a self-expanding frame, obtained from a nitinol wire, thermo-mechanically formed and mechanically crimped at five locations. This defines a set of arched ribs expanding into the atrium and two petal-like structures protruding into the ventricle between the native mitral leaflets, whose counteracting action generates the anchoring force, whilst limiting the systolic motion of the native anterior leaflet and the associated risk of left ventricular outflow tract obstruction. The wireframe configuration results in minimum metallic material, and relies on a skirt made from polymeric mesh (allowing integration from the host tissues), tensed between the atrial petals and the leaflets, to gently distribute the contact pressure over the annulus region. Paravalvular sealing is provided by a pericardial cuff extending around the entire framework of the valve, which inflates during systole as effect of the transvalvular closing pressure. The valve, designed in the presented version for transapical implantation, can be retrieved into the delivery system after complete expansion, using a similar mechanism to that described by the authors for a TAVI device.44
The structural numerical analyses, though inherently limited in their ability to represent the physics involved in heart valve leaflet closure, were adequate to predict the systolic function of the leaflets. In particular, this approximation does not take into account the interaction between the working fluid and the structural components, which determine the flow patterns and the pressure differences acting under real physiological conditions. Fluid structure interaction modelling would be more accurate for the simulation of the opening and closing leaflets dynamics. However, the peak of stress in the leaflets during the cardiac cycle is essentially led by the closing transvalvular pressure load,33 so that neglecting the local pressure variation and fluid shear stresses due to blood flow can still yield to sufficiently accurate results for the design evaluation stage.10
The valve wireframe optimisation was carried out until obtaining an optimal geometry which has lower stresses than NiTi yielding. Portions 5 and 6 in Fig. 2a were imposed by the leaflets geometry and kept unchanged for all wireframe models. The geometry of the wireframe is relatively complex, and includes a number of geometric parameters which needed to be optimised to obtain a suitable design. Each section was iteratively modified to minimise local stresses, resulting in a final geometry which fits adequately into the host mitral anatomy, maintaining acceptable levels of stress in the crimped configuration. The finite element analyses of a wireframe crimped to a diameter of 8 mm resulted in a maximum stress less than 900 MPa, which corresponds to a typical yield stress for Nitinol.46 The stress concentrations were predicted in the vicinity of the crimping sleeves, with local maxima around 600 MPa. Therefore, plastic deformation is not expected in the crimped wireframe, and this was confirmed by loading and unloading the physical prototype in an 8 mm diameter tube multiple times, without observable changes in shape. Besides, the presented version of the wireframe is designed to be ideally implantable from transapical route, which tolerates the use of larger sheath profiles (up to 33 French, 11 mm), resulting in further reduction of the stresses on the NiTi wireframe.60 Crimping of the TMV wireframe was simulated by gradually shrinking a cylindrical contact surface surrounding the prosthesis along its entire length. In the current application, the valve distal loops (Fig. 2a, portions 1 and 2) are engaged by a set of tethers, used to pull the valve into the catheter from the side at the outflow.45 Nevertheless, the resulting geometry of the crimped wireframe in the numerical simulations resulted visually accurate.
The valve design and prototypes were of a nominal size equal to 26 mm, corresponding to the largest inter-trigonal dimension of the prosthetic leaflets. This is suitable for patient’s annuli with inter-trigonal diameters equal or lower than 25 mm. Though this range is smaller than the average size in adult humans, it is more suitable for preclinical in vivo evaluation in ovine models,43 which is expected to be one of the next developmental steps. The prototypes were tested in mock host annuli of inter-trigonal diameters ranging from 21 to 25 mm. As expected, the diastolic transmitral pressure difference raised nonlinearly as the dimensions of the host annulus reduced, increasing from about 5 mmHg for the 25 mm annulus, to about 9 mmHg for the 21 mm annulus. A high peak in the initial diastolic transmitral pressure drop is measured in the tests (up to 45 mmHg). This is often observed in tests performed on hydro-mechanical pulse duplicators,16,28,29,48,53,55 and could be due to the non-physiological ventricular compliance, which may determine steeper flow waves and higher pressure gradients associated with early passive filling during ventricular relaxation. The calculated EOA well reflected the variation in the area of the implantation annulus, varying proportionally. Regurgitant fraction did not show a clear pattern associated with the implantation size for the different prototypes, although the mean value reduced progressively from 21 to 24 mm, inverting the trend at 25 mm. The reduction with the size may be associated with the different length of the mock native leaflets, which were designed proportional to the annulus size and, therefore, provided different covering of the sealing cuff of the prosthetic valves. On the other hand, the increased regurgitant fraction in the 25 mm annulus may be justified by the presence of gaps between the device and the mitral annulus. Globally, the device met the hydrodynamic requirements requested for transcatheter mitral valves in the standard ISO5840-3:2013, for all implantation sizes. Direct comparison of the hydrodynamic performance with competing solutions is not possible, as these are not available in the market and no in vitro data quantifying their diastolic and systolic efficiency have been published. However, measured values of transmitral diastolic pressure drops are consistent with those reported for transcatheter mitral implantation of off-label TAVI devices in failed mitral valve bioprostheses or annuloplasty rings, and in severe calcific mitral stenosis.13,18 Regurgitant fractions were inferior to those previously measured on the same system for commercially available TAVI devices.45 This is very encouraging, in consideration of the fact that, for the mitral position, closure is associated with higher transvalvular pressure drop and longer durations with respect to the cardiac cycle.
In terms of anchoring, no migration was observed for any of the test configurations, covering host annuli with inter-trigonal diameters between 21 and 25 mm. However, it needs to be taken into account that the mock host valves did not model the physiological contraction, and cordae tendineae and papillary muscles were absent. Ex vivo isolated beating heart or pressurised animal heart platforms17,57 and acute in animal trials could provide more reliable insights on the fitting and performance of a transcatheter valve.44 These studies would also be essential to verify the efficacy of the anchoring mechanism to avoid left ventricular outflow tract obstruction by preventing the systolic motion of the native anterior leaflet.
A novel TMV was developed, consisting of two bovine pericardial leaflets designed to ensure proper functionality across a range of implantation configurations and a sealing cuff, supported by a wireframe, optimised to minimise stresses whilst crimped. The device exceeded the minimum performance requirement from the international standards, thereby proving its feasibility as a mitral valve substitute to treat mitral regurgitation. In vitro durability assessment of the valve by means of accelerated cyclic tests is now being conducted, with the aim of verifying that the solution guarantees a survival equal or superior to the requirement for flexible leaflets heart valves (200 × 106 cycles). The next steps in the development will include in vivo preclinical evaluation by means of in animal implants (possibly complemented by ex vivo studies), to validate the design principles and the efficacy of the device.
If these will confirm the predicted performance, the proposed device could provide a viable alternative to transcatheter repair techniques and, due to its geometric similarity to the human mitral valve anatomy, may result a more appropriate option compared to the other TMVs in development.
This work was supported by the British Heart Foundation (PG/13/78/30400). Authors wish also to acknowledge Dr Benyamin Rahmani and Dr Michael Mullen for their assistance and advices, and Lithotech Medical for their support in the frames manufacturing.
Conflict of interest
The authors do not have any conflict of interest to declare.
Supplementary material 1 (MOV 21234 kb)
Supplementary material 2 (MOV 20581 kb)
- 1.Abdul-Jawad Altisent, O., E. Dumont, F. Dagenais, M. Sénéchal, M. Bernier, K. O’Connor, S. Bilodeau, J. M. Paradis, F. Campelo-Parada, R. Puri, M. Del Trigo, and J. Rodés-Cabau. Initial experience of transcatheter mitral valve replacement with a novel transcatheter mitral valve: procedural and 6-month follow-up results. J. Am. Coll. Cardiol. 66:1011–1019, 2015.CrossRefPubMedGoogle Scholar
- 2.Abdul-Jawad Altisent, O., E. Dumont, F. Dagenais, M. Sénéchal, M. Bernier, K. O’Connor, J.-M. Paradis, S. Bilodeau, S. Pasian, and J. Rodés-Cabau. Transcatheter mitral valve implantation With the FORTIS device: insights into the evaluation of device success. JACC Cardiovasc. Interv. 8:994–995, 2015.CrossRefPubMedGoogle Scholar
- 3.Acker, M. A., M. K. Parides, L. P. Perrault, A. J. Moskowitz, A. C. Gelijns, P. Voisine, P. K. Smith, J. W. Hung, E. H. Blackstone, J. D. Puskas, M. Argenziano, J. S. Gammie, M. Mack, D. D. Ascheim, E. E. Bagiella, E. G. Moquete, T. B. Ferguson, K. A. Horvath, N. L. Geller, M. A. Miller, Y. J. Woo, D. A. D’Alessandro, G. Ailawadi, F. Dagenais, T. J. Gardner, P. T. O’Gara, R. E. Michler, I. L. Kron, and CTSN. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N. Engl. J. Med. 370:23–32, 2014.CrossRefPubMedGoogle Scholar
- 5.Andalib, A., S. Mamane, I. Schiller, A. Zakem, D. Mylotte, G. Martucci, P. Lauzier, W. Alharbi, R. Cecere, M. Dorfmeister, R. Lange, J. Brophy, and N. Piazza. A systematic review and meta-analysis of surgical outcomes following mitral valve surgery in octogenarians: implications for transcatheter mitral valve interventions. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 9:1225–1234, 2014.Google Scholar
- 8.Bapat, V., L. Buellesfeld, M. D. Peterson, J. Hancock, D. Reineke, C. Buller, T. Carrel, F. Praz, R. Rajani, N. Fam, H. Kim, S. Redwood, C. Young, C. Munns, S. Windecker, and M. Thomas. Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 10:U120–U128, 2014.Google Scholar
- 11.Calafiore, A. M., S. Gallina, A. L. Iacò, M. Contini, A. Bivona, M. Gagliardi, P. Bosco, and M. Di Mauro. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. Ann. Thorac. Surg. 87:698–703, 2009.CrossRefPubMedGoogle Scholar
- 14.Cheung, A., D. Stub, R. Moss, R. H. Boone, J. Leipsic, S. Verheye, S. Banai, and J. Webb. Transcatheter mitral valve implantation with Tiara bioprosthesis. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 10:U115–U119, 2014.Google Scholar
- 16.De Gaetano, F., M. Serrani, P. Bagnoli, J. Brubert, J. Stasiak, G. D. Moggridge, and M. L. Costantino. Fluid dynamic characterization of a polymeric heart valve prototype (Poli-Valve) tested under continuous and pulsatile flow conditions. Int. J. Artif. Organs 38:600–606, 2015.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Eleid, M. F., A. K. Cabalka, M. R. Williams, B. K. Whisenant, O. O. Alli, N. Fam, P. M. Pollak, F. Barrow, J. F. Malouf, R. A. Nishimura, L. D. Joyce, J. A. Dearani, and C. S. Rihal. Percutaneous transvenous transseptal transcatheter valve implantation in failed bioprosthetic mitral valves, ring annuloplasty, and severe mitral annular calcification. JACC Cardiovasc. Interv. 9:1161–1174, 2016.CrossRefPubMedGoogle Scholar
- 20.Gillinov, A. M., E. H. Blackstone, E. R. Nowicki, W. Slisatkorn, G. Al-Dossari, D. R. Johnston, K. M. George, P. L. Houghtaling, B. Griffin, J. F. Sabik, and L. G. Svensson. Valve repair versus valve replacement for degenerative mitral valve disease. J. Thorac. Cardiovasc. Surg. 135:885–893, 2008.CrossRefPubMedGoogle Scholar
- 22.Grossi, E. A., N. Patel, Y. J. Woo, J. D. Goldberg, C. F. Schwartz, V. Subramanian, T. Feldman, R. Bourge, N. Baumgartner, C. Genco, S. Goldman, M. Zenati, J. A. Wolfe, Y. K. Mishra, N. Trehan, S. Mittal, S. Shang, T. J. Mortier, C. J. Schweich, and RESTOR-MV Study Group. Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J. Am. Coll. Cardiol. 56:1984–1993, 2010.CrossRefPubMedGoogle Scholar
- 23.Guerrero, M., A. B. Greenbaum, and W. O’neill. Early experience with transcatheter mitral valve replacement. Card. Interv. Today 2015:61–67, 2015.Google Scholar
- 24.Harnek, J., J. G. Webb, K.-H. Kuck, C. Tschope, A. Vahanian, C. E. Buller, S. K. James, C. P. Tiefenbacher, and G. W. Stone. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation). JACC Cardiovasc. Interv. 4:115–122, 2011.CrossRefPubMedGoogle Scholar
- 26.Hülsmann, J., K. Grün, S. El Amouri, M. Barth, K. Hornung, C. Holzfuß, A. Lichtenberg, and P. Akhyari. Transplantation material bovine pericardium: biomechanical and immunogenic characteristics after decellularization vs. glutaraldehyde-fixing. Xenotransplantation 19:286–297, 2012.CrossRefPubMedGoogle Scholar
- 30.Kheradvar, A., E. M. Groves, C. A. Simmons, B. Griffith, S. H. Alavi, R. Tranquillo, L. P. Dasi, A. Falahatpisheh, K. J. Grande-Allen, C. J. Goergen, M. R. K. Mofrad, F. Baaijens, S. Canic, and S. H. Little. Emerging trends in heart valve engineering: part III. Novel technologies for mitral valve repair and replacement. Ann. Biomed. Eng. 43:858–870, 2015.CrossRefPubMedGoogle Scholar
- 34.Maisano, F., N. Buzzatti, M. Taramasso, and O. Alfieri. Mitral Transcatheter Technologies. Rambam Maimonides Med. J. 4:, 2013.Google Scholar
- 35.Maisano, F., O. Alfieri, S. Banai, M. Buchbinder, A. Colombo, V. Falk, T. Feldman, O. Franzen, H. Herrmann, S. Kar, K.-H. Kuck, G. Lutter, M. Mack, G. Nickenig, N. Piazza, M. Reisman, C. E. Ruiz, J. Schofer, L. Søndergaard, G. W. Stone, M. Taramasso, M. Thomas, A. Vahanian, J. Webb, S. Windecker, and M. B. Leon. The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement? Eur. Heart J. 36:1651–1659, 2015.CrossRefPubMedGoogle Scholar
- 37.Maisano, F., V. Falk, M. A. Borger, H. Vanermen, O. Alfieri, J. Seeburger, S. Jacobs, M. Mack, and F. W. Mohr. Improving mitral valve coaptation with adjustable rings: outcomes from a European multicentre feasibility study with a new-generation adjustable annuloplasty ring system. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 44:913–918, 2013.CrossRefGoogle Scholar
- 38.Meredith, I., V. Bapat, J. Morriss, M. McLean, and B. Prendergast. Intrepid transcatheter mitral valve replacement system: technical and product description. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 12:Y78–Y80, 2016.Google Scholar
- 39.Muller, D. W. M., R. S. Farivar, P. Jansz, R. Bae, D. Walters, A. Clarke, P. A. Grayburn, R. C. Stoler, G. Dahle, K. A. Rein, M. Shaw, G. M. Scalia, M. Guerrero, P. Pearson, S. Kapadia, M. Gillinov, A. Pichard, P. Corso, J. Popma, M. Chuang, P. Blanke, J. Leipsic, P. Sorajja, and Tendyne Global Feasibility Trial Investigators. Transcatheter mitral valve replacement for patients with symptomatic mitral regurgitation: a global feasibility trial. J. Am. Coll. Cardiol. 69:381–391, 2017.CrossRefPubMedGoogle Scholar
- 42.Puri, R., O. Abdul-Jawad Altisent, M. Del Trigo, F. Campelo-Parada, A. Regueiro, H. Barbosa Ribeiro, R. DeLarochellière, J.-M. Paradis, E. Dumont, and J. Rodés-Cabau. Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease: a systematic review. Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv. 87:540–548, 2016.CrossRefGoogle Scholar
- 44.Rahmani, B., S. Tzamtzis, R. Sheridan, M. J. Mullen, J. Yap, A. M. Seifalian, and G. Burriesci. A new transcatheter heart valve concept (the TRISKELE): feasibility in an acute preclinical model. EuroIntervention J. Eur. Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. 12:901–908, 2016.Google Scholar
- 47.Sack, S., P. Kahlert, L. Bilodeau, L. A. Pièrard, P. Lancellotti, V. Legrand, J. Bartunek, M. Vanderheyden, R. Hoffmann, P. Schauerte, T. Shiota, D. S. Marks, R. Erbel, and S. G. Ellis. Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ. Cardiovasc. Interv. 2:277–284, 2009.CrossRefPubMedGoogle Scholar
- 51.Sondergaard, L., M. Brooks, N. Ihlemann, A. Jonsson, S. Holme, M. Tang, K. Terp, and A. Quadri. Transcatheter mitral valve implantation via transapical approach: an early experience. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 48:873–877, 2015; (discussion 877–878).CrossRefGoogle Scholar
- 54.Thourani, V. H., W. S. Weintraub, R. A. Guyton, E. L. Jones, W. H. Williams, S. Elkabbani, and J. M. Craver. Outcomes and long-term survival for patients undergoing mitral valve repair versus replacement: effect of age and concomitant coronary artery bypass grafting. Circulation 108:298–304, 2003.CrossRefPubMedGoogle Scholar
- 61.Xuan, Y., Y. Moghaddam, K. Krishnan, D. Dvir, J. Ye, M. Hope, L. Ge, and E. Tseng. Impact of size of transcatheter aortic valves on stent and leaflet stresses. Book of Abstracts EuroPCR 2016, 2016, n. Euro16A-POS0558.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.